Symbol: CIPLA
Month: 2025-02
Start Price: ₹1439.50
End Price: ₹1407.50
12M Return: -2.22%
6M Return: -2.22%
3M Return: -2.22%
Volatility: 0.201
Sharpe Ratio: -1.384
Max Drawdown: -0.050
Peer Correlation (SUNPHARMA): 0.5507
Peer Correlation (DIVISLAB): 0.3046
Peer Correlation (GRASIM): 0.4135
Average Peer Correlation: 0.4229

Generate a short summary and suggest whether to BUY, SELL, or HOLD.

--- LLM Output ---
**Summary:**

Cipla's stock performance has been lackluster, with a 12-month return of -2.22%, indicating a decline in value. The volatility of 0.201 suggests moderate price fluctuations. The Sharpe Ratio of -1.384 indicates that the returns are not sufficient to compensate for the risk taken. The Max Drawdown of -0.050 suggests that the stock has experienced a moderate decline in value. Correlation analysis with peers, SunPharma, DivisLab, and Grasim, indicates a moderate correlation, suggesting that Cipla's performance is influenced by the pharma industry trends.

**Recommendation:**

Based on the analysis, I would recommend a **HOLD** position on Cipla. The stock's underperformance, high volatility, and low Sharpe Ratio suggest that it may not be the best investment opportunity at present. However, the moderate correlation with peers indicates that the stock is not entirely disconnected from the industry trends, and a turnaround in the pharma sector could benefit Cipla. It's essential to monitor the stock's performance and industry trends closely before making a buying or selling decision.